Candel Therapeutics, Inc. (CADL)

Candel Therapeutics, Inc. is trading at $11.95, down 1.73% on the session. The 50 day average sits at $9.67 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 71.2, which reads as overbought, and MACD is bullish crossover. Volume is volume spike.

The nearest support is around $9.19 with resistance near $11.95, so that band frames the current range. Average daily movement is roughly $0.59, or about 5.0% of the share price, which is what any stop placement has to allow for. The overall health score of 68 out of 100 combines a trend score of 75, momentum of 84 and a risk score of 36.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.